Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia

Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia

Abstract We investigated the metabolism and disposition of vornorexant, a novel dual orexin receptor antagonist, in rats and dogs, and clarified in vitro metabolite profiles in humans. Furthermore, we investigated the pharmacokinetics of active metabolites in rats and dogs and their CNS distribution...

Full description

Bibliographic Details
Main Authors: Yoshihiro Konno, Shunsuke Kamigaso, Hidetoh Toki, Shuichi Terasaka, Hirohiko Hikichi, Hiromi Endo, Jun‐Ichi Yamaguchi, Akiko Mizuno‐Yasuhira
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Pharmacology Research & Perspectives
Subjects:
disposition
half‐life
metabolism
orexin
pharmacokinetic
TS‐142
Online Access:https://doi.org/10.1002/prp2.1183

Internet

https://doi.org/10.1002/prp2.1183

Similar Items